Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Reprod Domest Anim ; 59(6): e14598, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38881434

RESUMEN

Our previous research has shown that melatonin (MLT) can reduce cryopreserved ovarian damage in mice. Yet, the molecular mechanism of MLT protection is still unclear. Some studies have shown that melatonin receptor 1 (MT1) is very important for animal reproductive system. To evaluate whether MLT exerts its protective effect on cryopreserved mice ovarian tissue via MT1, we added antagonist of MT1/MT2 (Luzindor) or antagonist of MT2 (4P-PDOT) to the freezing solution, followed by cryopreservation and thawing of ovarian tissue. The levels of total superoxide dismutase (T-SOD), catalase (CAT), nitric oxide (NO) and malondialdehyde (MDA) were detected. Besides, by using RT-PCR and Western blotting, the expression of Bcl-2, Bax and Nrf2/HO-1 signalling pathway-related proteins was detected. These findings demonstrated that compared with the melatonin group, the addition of Luzindor increased apoptosis, NO and MDA activities, decreased CAT and T-SOD activities and inhibited Nrf2/HO-1 signalling pathway. In conclusion, melatonin can play a protective role in cryopreserved ovarian tissue of mice through MT1 receptor.


Asunto(s)
Criopreservación , Melatonina , Factor 2 Relacionado con NF-E2 , Ovario , Estrés Oxidativo , Receptor de Melatonina MT1 , Transducción de Señal , Animales , Femenino , Melatonina/farmacología , Estrés Oxidativo/efectos de los fármacos , Ovario/efectos de los fármacos , Receptor de Melatonina MT1/metabolismo , Receptor de Melatonina MT1/genética , Transducción de Señal/efectos de los fármacos , Factor 2 Relacionado con NF-E2/metabolismo , Factor 2 Relacionado con NF-E2/genética , Ratones , Criopreservación/veterinaria , Triptaminas/farmacología , Apoptosis/efectos de los fármacos , Hemo Oxigenasa (Desciclizante)/metabolismo , Hemo Oxigenasa (Desciclizante)/genética , Óxido Nítrico/metabolismo , Malondialdehído/metabolismo , Proteínas de la Membrana , Hemo-Oxigenasa 1
2.
Eur J Med Res ; 29(1): 218, 2024 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-38576041

RESUMEN

BACKGROUND: The objective of this investigation is to analyze the levels and clinical relevance of serum PYCARD (Pyrin and CARD domain-containing protein, commonly known as ASC-apoptosis-associated speck-like protein containing a caspase activation and recruitment domain), interleukin-38 (IL-38), and interleukin-6 (IL-6) in individuals afflicted with rheumatoid arthritis (RA). METHODS: Our study comprised 88 individuals diagnosed with RA who sought medical attention at the Affiliated Hospital of Chengde Medical University during the period spanning November 2021 to June 2023, constituting the test group. Additionally, a control group of 88 individuals who underwent health assessments at the same hospital during the aforementioned timeframe was included for comparative purposes. The study involved the assessment of IL-38, IL-6, PYCARD, anti-cyclic citrullinated peptide antibody (anti-CCP), and erythrocyte sedimentation rate (ESR) levels in both groups. The research aimed to explore the correlations and diagnostic efficacy of these markers, employing pertinent statistical analyses for comprehensive evaluation. RESULTS: The test group had higher expression levels of PYCARD, IL-6, and IL-38 than the control group (P < 0.05). Based on the correlation analysis, there was a strong relationship between PYCARD and IL-38 (P < 0.01). The receiver operating characteristic (ROC) curve analysis revealed area under the curve (AUC) values of 0.97, 0.96, and 0.96 when using combinations of PYCARD and anti-CCP, IL-38 and anti-CCP, and IL-6 and anti-CCP for predicting RA, respectively. Importantly, all three of these pairs demonstrated superior AUC values compared to PYCARD, IL-38, IL-6, ESR, or anti-CCP used as standalone diagnostic indicators. CONCLUSION: PYCARD, IL-6, and IL-38 exhibit promising potential as novel diagnostic markers and may constitute valuable tools for supporting the diagnosis of RA.


Asunto(s)
Anticuerpos Antiproteína Citrulinada , Artritis Reumatoide , Humanos , Interleucina-6 , Artritis Reumatoide/diagnóstico , Autoanticuerpos , Curva ROC , Péptidos Cíclicos , Biomarcadores , Proteínas Adaptadoras de Señalización CARD/genética , Interleucinas
3.
Eur J Orthop Surg Traumatol ; 25(1): 135-9, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24816760

RESUMEN

The objective of this randomized controlled trial was to evaluate the efficacy and safety of intra-articular injections of tranexamic acid (TXA) on perioperative blood loss and transfusion in primary unilateral total knee arthroplasty (TKA) without drainage. Primary TKA was performed on a total of 80 patients (80 knees) affected to various degrees by knee osteoarthritis. The patients were randomized to receive 500 mg of TXA in 20 mL of normal saline solution (n = 40) or an equivalent volume of normal saline solution (n = 40), applied into the joint for 5 min at the end of surgery. Data on routine blood examination, blood loss and blood transfusion after TKA were compared between the two groups. The results showed no significant difference between the two groups in intra-operative blood loss (P = 0.136). The mean postoperative visible blood loss, hidden blood loss and transfusion requests were significantly different between the two groups (P < 0.05). The values of postoperative hemoglobin and hematocrit were lower in the control group compared with those in the treatment group (P < 0.05). No deep vein thrombosis was detected through Doppler ultrasound examination. Three hour postoperative D-dimer in the control group was higher than the treatment group (P = 0.02). There was no statistically significant difference between the coagulation indicators and range of motion in the two groups. We conclude that intra-articular TXA in patients undergoing unilateral TKA could significantly reduce postoperative blood loss and blood transfusion and avoid perioperative anemia-related complications without increased risk of venous thrombosis.


Asunto(s)
Antifibrinolíticos/administración & dosificación , Artroplastia de Reemplazo de Rodilla/métodos , Hemorragia Posoperatoria/prevención & control , Ácido Tranexámico/administración & dosificación , Anciano , Anciano de 80 o más Años , Antifibrinolíticos/efectos adversos , Artroplastia de Reemplazo de Rodilla/efectos adversos , Pruebas de Coagulación Sanguínea , Pérdida de Sangre Quirúrgica , Transfusión Sanguínea , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/efectos de los fármacos , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Hematócrito , Hemoglobinas/efectos de los fármacos , Hemoglobinas/metabolismo , Humanos , Inyecciones Intraarticulares , Articulación de la Rodilla/fisiología , Masculino , Rango del Movimiento Articular , Ácido Tranexámico/efectos adversos , Trombosis de la Vena/inducido químicamente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...